Literature DB >> 16160166

Inactivation of retroviruses with preservation of structural integrity by targeting the hydrophobic domain of the viral envelope.

Yossef Raviv1, Mathias Viard, Julian W Bess, Elena Chertova, Robert Blumenthal.   

Abstract

We describe a new approach for the preparation of inactivated retroviruses for vaccine application. The lipid domain of the viral envelope was selectively targeted to inactivate proteins and lipids therein and block fusion of the virus with the target cell membrane. In this way, complete elimination of the infectivity of human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) could be achieved with preservation of antigenic determinants on the surface of the viral envelope. Inactivation was accomplished by modification of proteins and lipids in the viral envelope using the hydrophobic photoinduced alkylating probe 1,5 iodonaphthylazide (INA). Treatment of HIV and SIV isolates with INA plus light completely blocked fusion of the viral envelope and abolished infectivity. The inactivated virus remained structurally unchanged, with no detectable loss of viral proteins. Modifications to envelope and nucleocapsid proteins were detected by changes in their elution pattern on reverse-phase high-performance liquid chromatography. These modifications had no effect on primary and secondary structure epitopes as determined by monoclonal antibodies. Likewise, the inactivated HIV reacted as well as the live virus with the conformation-sensitive and broadly neutralizing anti-HIV type 1 monoclonal antibodies 2G12, b12, and 4E10. Targeting the lipid domain of biological membranes with hydrophobic alkylating compounds could be used as a general approach for inactivation of enveloped viruses and other pathogenic microorganisms for vaccine application.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16160166      PMCID: PMC1211527          DOI: 10.1128/JVI.79.19.12394-12400.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.

Authors:  T W Baba; V Liska; R Hofmann-Lehmann; J Vlasak; W Xu; S Ayehunie; L A Cavacini; M R Posner; H Katinger; G Stiegler; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; Y Lu; J E Wright; T C Chou; R M Ruprecht
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

2.  Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS.

Authors:  W G Rice; J G Supko; L Malspeis; R W Buckheit; D Clanton; M Bu; L Graham; C A Schaeffer; J A Turpin; J Domagala; R Gogliotti; J P Bader; S M Halliday; L Coren; R C Sowder; L O Arthur; L E Henderson
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

3.  Conservation of HIV-1 gp120 neutralizing epitopes after formalin inactivation.

Authors:  Q J Sattentau
Journal:  AIDS       Date:  1995-12       Impact factor: 4.177

4.  Selective photoinduced uncoupling of the response of adenylate cyclase to gonadotropins by 5-iodonaphthyl 1-azide.

Authors:  Y Raviv; T Bercovici; C Gitler; Y Salomon
Journal:  Biochemistry       Date:  1984-01-31       Impact factor: 3.162

5.  Photoinactivation and kinetics of membrane fusion mediated by the human immunodeficiency virus type 1 envelope glycoprotein.

Authors:  D S Dimitrov; R Blumenthal
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

6.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

Authors:  D R Burton; J Pyati; R Koduri; S J Sharp; G B Thornton; P W Parren; L S Sawyer; R M Hendry; N Dunlop; P L Nara
Journal:  Science       Date:  1994-11-11       Impact factor: 47.728

7.  Inactivation of the human immunodeficiency virus type 1 (HIV-1) by ultraviolet and X irradiation.

Authors:  E E Henderson; G Tudor; J Y Yang
Journal:  Radiat Res       Date:  1992-08       Impact factor: 2.841

8.  A multistep procedure for the chemical inactivation of human immunodeficiency virus for use as an experimental vaccine.

Authors:  E Race; C A Stein; M D Wigg; A Baksh; M Addawe; P Frezza; J S Oxford
Journal:  Vaccine       Date:  1995-11       Impact factor: 3.641

9.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.

Authors:  A Trkola; M Purtscher; T Muster; C Ballaun; A Buchacher; N Sullivan; K Srinivasan; J Sodroski; J P Moore; H Katinger
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

10.  Inactivation of free and cell-associated human immunodeficiency virus in platelet suspensions by aminomethyltrimethylpsoralen and ultraviolet light.

Authors:  L E Benade; J Shumaker; Y Xu; X Chen; R Y Dodd
Journal:  Transfusion       Date:  1994-08       Impact factor: 3.157

View more
  16 in total

1.  Application of methods for viral clearance in stem cell production.

Authors:  Fernando Cobo
Journal:  In Vitro Cell Dev Biol Anim       Date:  2007-10-13       Impact factor: 2.416

2.  Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4'-aminomethyl-trioxsalen) is highly immunogenic in mice.

Authors:  Kanakatte Raviprakash; Peifang Sun; Yossef Raviv; Thomas Luke; Nicholas Martin; Tadeusz Kochel
Journal:  Hum Vaccin Immunother       Date:  2013-07-08       Impact factor: 3.452

3.  Effects of UVA irradiation, aryl azides, and reactive oxygen species on the orthogonal inactivation of the human immunodeficiency virus (HIV-1).

Authors:  Julie M Belanger; Yossef Raviv; Mathias Viard; M Jason de la Cruz; Kunio Nagashima; Robert Blumenthal
Journal:  Virology       Date:  2011-07-02       Impact factor: 3.616

4.  Proof-of-concept for a virus-induced obesity vaccine; vaccination against the obesity agent adenovirus 36.

Authors:  H-N Na; J-H Nam
Journal:  Int J Obes (Lond)       Date:  2014-03-11       Impact factor: 5.095

5.  Characterization of the effects of aryl-azido compounds and UVA irradiation on the viral proteins and infectivity of human immunodeficiency virus type 1.

Authors:  Julie M Belanger; Yossef Raviv; Mathias Viard; Michael Jason de la Cruz; Kunio Nagashima; Robert Blumenthal
Journal:  Photochem Photobiol       Date:  2010 Sep-Oct       Impact factor: 3.421

6.  Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity.

Authors:  Yossef Raviv; Robert Blumenthal; S Mark Tompkins; Jennifer Humberd; Robert J Hogan; Mathias Viard
Journal:  J Virol       Date:  2008-02-27       Impact factor: 5.103

7.  HIV-1 envelope glycoprotein-mediated fusion and pathogenesis: implications for therapy and vaccine development.

Authors:  Amy Jacobs; Himanshu Garg; Mathias Viard; Yossef Raviv; Anu Puri; Robert Blumenthal
Journal:  Vaccine       Date:  2008-01-10       Impact factor: 3.641

8.  Orthogonal inactivation of influenza and the creation of detergent resistant viral aggregates: towards a novel vaccine strategy.

Authors:  Julie M Belanger; Yossef Raviv; Mathias Viard; Ulrich Baxa; Robert Blumenthal
Journal:  Virol J       Date:  2012-03-26       Impact factor: 4.099

9.  Inactivation of avian influenza viruses by hydrostatic pressure as a potential vaccine development approach.

Authors:  Shana Priscila Coutinho Barroso; Ana Clara Vicente Dos Santos; Patrícia Souza Dos Santos; José Nelson Dos Santos Silva Couceiro; Davis Fernandes Ferreira; Dirlei Nico; Alexandre Morrot; Jerson Lima Silva; Andrea Cheble de Oliveira
Journal:  Access Microbiol       Date:  2021-04-13

10.  Inactivation of Chikungunya virus by 1,5 iodonapthyl azide.

Authors:  Anuj Sharma; Paridhi Gupta; Radha K Maheshwari
Journal:  Virol J       Date:  2012-12-04       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.